Back to Authors

Friedman, Paul M.

0009-0006-1204-6403

Mayo Clinic

Houston Methodist

Citations 2

Histological analysis of laser‐enabled tissue coring with a novel 2910 nm erbium‐doped fluoride glass fiber laser
Murray, Taryn N. , Maredia, Hasina , Friedman, Paul M.

Lasers in Surgery and Medicine | May 8, 2024 | Volume: 56 | Issue: 5 | Pages: 462-465

10.1002/lsm.23792 Get It

AbstractObjectivesThere remains an unmet need for a laser‐enabled tissue coring device that can effectively improve face and neck skin laxity and rhytides. We investigate a novel 2910 nm erbium‐doped fluoride glass fiber laser (2910 nm fiber laser) (UltraClear; Acclaro Medical) for laser‐coring of submental tissue.MethodsFive subjects, Glogau scale III−IV, were treated with a single pulse of the laser‐coring mode of the 2910 nm fiber laser in the submentum. A 4 mm punch biopsy was immediately performed. Biopsy specimens were sectioned and stained with hematoxylin and eosin and placed on glass slides. All sections were reviewed, and sections containing the center of the transected core were analyzed for depth and diameter of the ablative microchannel and width of the surrounding zone of coagulation.ResultsA total of 15 intact micro‐cores were analyzed. Histological analysis revealed an average ± standard deviation microchannel diameter of 242.5 ± 65.2 µm, an average ablative depth of 980 ± 318.8 µm, and an average zone of coagulation of 104 ± 32 µm.ConclusionsLaser‐enabled tissue coring with a novel 2910 nm fiber laser can safely achieve a wider microchannel diameter with ablative depth extending to the mid and deep dermis, which has the potential for collagen contraction and tissue tightening. Laser‐coring to this ablation diameter and depth and with the surrounding zone of coagulation was found to be safe without adverse effects of post‐inflammatory erythema or scarring in our study.
Largest comparative analysis: Novel large spot size 595 nm, high‐energy, pulsed dye laser reduces number of treatments for improvement of adult and pediatric port wine birthmarks
Sodha, Pooja , Aboul‐Fettouh, Nader , Martin, Katherine , Geronemus, Roy G. , Friedman, Paul M. , Aboul-Fettouh, Nader, Wang, Jordan V.

Lasers in Surgery and Medicine | June 9, 2023 | Volume: 55 | Issue: 8 | Pages: 741-747

10.1002/lsm.23693 Get It

AbstractObjectivePort wine birthmarks (PWBs) are vascular malformations affecting 0.3%–0.5% of newborns with the tendency to persist into adulthood without adequate treatment of the heterogenous ectatic vessels. This study compares treatment outcomes and parameters of the prior generation pulsed dye laser (PPDL) and the larger spot novel generation pulsed dye laser (NPDL) to establish whether a larger spot size laser provides greater clearance with fewer treatments.MethodsOne hundred and sixty patients were treated with either the PPDL (80 patients) and NPDL (80 patients) with retrospective review of age, body site, laser treatment parameters, number of treatments, and improvement following laser therapy.ResultsPatients treated with PPDL were older on average than patients treated with NPDL (mean 24.8 ± 19.7 vs. mean 17.1± 19.3 years, p < 0.05). The majority of lesions treated with PPDL were located on the face and neck, whereas truncal and extremity sites were more frequently treated with the NPDL. Use of NPDL was associated with a mean maximum spot size of 13.1 mm and mean maximum fluence of 7.3 J/cm2 with pulse durations of 0.45–3 ms, whereas use of the PPDL was associated with a mean spot size of 10.8 mm and mean maximum fluence of 8.8 J/cm2 with pulse durations of 0.45–6 ms. Fifty percent improvement was seen with 8.8 PPDL treatments compared to 4.3 NPDL treatments (p ≤ 0.01) with no significant difference in overall mean improvement between both devices at the chosen parameters. Multiple regression analysis showed that device type, not age or lesion location, was the only statistically significant independent variable to affect the endpoint of at least 50% improvement of the lesion.ConclusionsUse of the larger spot NPDL is associated with achieving 50% improvement with fewer treatments.